Infantile Hemangiomas(IH) are the most common benign tumors of childhood, with occurrence rate of 5%-10%, and up to 60% of the tumors presenting in the head and neck region while females are more common than males. The tumor has a unique evolution including proliferation, stabilization and slow involution. About 10% of the IHs have the potential for complications such as hemorrhage, ulceration, disfigurement, associated dysfunctions and rarely death. Many IHs leave permanent sequelae, with the potential psychological effects on the children and their parents. Therefore, early intervention is needed. 

Oral propranolol, a nonselective beta-blocker, is the first and the only FDA-approved medication for IHs. It is most effective during the proliferative phase. However, there are some potential systemic adverse effect of oral propranolol, for example hypotension, bradycardia, sleep disturbances, etc. Therefore, it is necessary to develop local administration of beta-blocker to avoid systemic adverse effects in treating small, superficial IHs while maintaining the efficacy.